Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Sell
5
ARVN Quote, Financials, Valuation and Earnings
Last price:
$8.70
Seasonality move
:
-15.98%
Day range:
$8.38 - $8.83
52-week range:
$7.91 - $44.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.30x
P/B ratio:
1.03x
Volume:
2.6M
Avg. volume:
2.4M
1-year change:
-80.23%
Market cap:
$579.1M
Revenue:
$263.4M
EPS (TTM):
-$2.77
Analysts' Opinion
-
Consensus RatingArvinas has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.26, Arvinas has an estimated upside of 437.57% from its current price of $8.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $8.42.
Fair Value
-
According to the consensus of 18 analysts, Arvinas has 437.57% upside to fair value with a price target of $45.26 per share.
ARVN vs. S&P 500
-
Over the past 5 trading days, Arvinas has overperformed the S&P 500 by 0.09% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arvinas does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arvinas has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Arvinas reported revenues of $59.2M.
Earnings Growth
-
Arvinas has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arvinas reported earnings per share of -$0.63.
Enterprise value:
-459.7M
EV / Invested capital:
-0.82x
Price / LTM sales:
2.30x
EV / EBIT:
--
EV / Revenue:
-1.75x
PEG ratio (5yr expected):
-1.15x
EV / Free cash flow:
1.76x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-16.42%
Net Income Margin (TTM):
-75.51%
Return On Equity:
-32.96%
Return On Invested Capital:
-32.92%
Operating Margin:
-98.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $131.3M | $78.5M | $263.4M | -$43.1M | $59.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$263.4M | -$401.5M | -$250.3M | -$165.3M | -$58.2M | |
| EBITDA | -$255.2M | -$394.8M | -$243.7M | -$163.6M | -$56.6M | |
| Diluted EPS | -$5.32 | -$6.50 | -$2.77 | -$2.53 | -$0.63 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $703.1M | $1.6B | $1.2B | $1.3B | $1.1B | |
| Total Assets | $717.4M | $1.6B | $1.3B | $1.3B | $1.1B | |
| Current Liabilities | $49.2M | $261.7M | $295.1M | $257.1M | $229.8M | |
| Total Liabilities | $75.2M | $799.9M | $703.9M | $644.6M | $529.7M | |
| Total Equity | $642.2M | $781.7M | $564.9M | $660M | $561.7M | |
| Total Debt | $2M | $1M | $1M | $800K | $600K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$273.5M | -$347.8M | -$259.3M | -$83.1M | -$84.1M | |
| Cash From Investing | $242.8M | $203.5M | $34.7M | -$53.7M | $98.9M | |
| Cash From Financing | $4.7M | $374.7M | $7.9M | $334.8M | $500K | |
| Free Cash Flow | -$280.3M | -$350.7M | -$261.1M | -$83.2M | -$84.4M | |
ARVN
Sector
Market Cap
$579.1M
$37.4M
Price % of 52-Week High
18.77%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-80.24%
-38.36%
Beta (5-Year)
1.954
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.97
200-day SMA
Sell
Level
$23.46
Bollinger Bands (100)
Sell
Level
15.75 - 25.33
Chaikin Money Flow
Sell
Level
-39.1M
20-day SMA
Sell
Level
$14.97
Relative Strength Index (RSI14)
Sell
Level
24.92
ADX Line
Sell
Level
27.22
Williams %R
Buy
Level
-95.4032
50-day SMA
Sell
Level
$17.03
MACD (12, 26)
Sell
Level
-2.58
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-12.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0651)
Sell
CA Score
(Annual)
Level (-1.2755)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9574)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Stock Forecast FAQ
In the current month, ARVN has received 13 Buy ratings 5 Hold ratings, and 0 Sell ratings. The ARVN average analyst price target in the past 3 months is $45.26.
-
Where Will Arvinas Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arvinas share price will rise to $45.26 per share over the next 12 months.
-
What Do Analysts Say About Arvinas?
Analysts are divided on their view about Arvinas share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arvinas is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Arvinas's Price Target?
The price target for Arvinas over the next 1-year time period is forecast to be $45.26 according to 18 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is ARVN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arvinas is a Buy. 13 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARVN?
You can purchase shares of Arvinas via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arvinas shares.
-
What Is The Arvinas Share Price Today?
Arvinas was last trading at $8.70 per share. This represents the most recent stock quote for Arvinas. Yesterday, Arvinas closed at $8.42 per share.
-
How To Buy Arvinas Stock Online?
In order to purchase Arvinas stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.72% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 5.74% over the past day.
